Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ROSG [NASD]
Rosetta Genomics, Ltd.
Index- P/E- EPS (ttm)-1.00 Insider Own- Shs Outstand11.70M Perf Week1.38%
Market Cap34.28M Forward P/E- EPS next Y-1.42 Insider Trans- Shs Float11.70M Perf Month-17.23%
Income-13.80M PEG- EPS next Q-0.19 Inst Own8.70% Short Float0.63% Perf Quarter-25.06%
Sales0.80M P/S42.85 EPS this Y42.90% Inst Trans- Short Ratio0.99 Perf Half Y-27.65%
Book/sh1.84 P/B1.59 EPS next Y-5.20% ROA-110.90% Target Price12.00 Perf Year-8.44%
Cash/sh1.69 P/C1.73 EPS next 5Y25.00% ROE-119.60% 52W Range2.35 - 6.69 Perf YTD0.34%
Dividend- P/FCF9.52 EPS past 5Y49.80% ROI-56.80% 52W High-56.20% Beta-2.68
Dividend %- Quick Ratio13.90 Sales past 5Y- Gross Margin-25.00% 52W Low24.68% ATR0.23
Employees45 Current Ratio13.90 Sales Q/Q500.00% Oper. Margin- RSI (14)37.04 Volatility8.86% 6.67%
OptionableYes Debt/Eq0.00 EPS Q/Q95.50% Profit Margin- Rel Volume0.86 Prev Close3.02
ShortableYes LT Debt/Eq0.00 EarningsNov 24 Payout- Avg Volume75.83K Price2.93
Recom2.00 SMA20-9.33% SMA50-16.47% SMA200-27.30% Volume64,996 Change-2.98%
30-Oct-13Downgrade Aegis Capital Buy → Hold $10 → $3.50
21-Oct-14 08:15AM  Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic Marketwired
13-Oct-14 08:30AM  Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells GlobeNewswire
19-Sep-14 09:00AM  ROSG: Rosetta Genomics Reports Better Than Expected Financial Results for 1H2014 Zacks Small Cap Research -5.24%
18-Sep-14 07:07AM  Half Year 2014 Rosetta Genomics Ltd Earnings Release - Time Not Supplied CCBN
17-Sep-14 04:20PM  Rosetta Genomics Reports Financial Results for the First Half of 2014 Marketwired +9.52%
10-Sep-14 08:45AM  Rosetta Genomics to Host Business Update Conference Call on September 18, 2014 Marketwired +7.29%
03-Sep-14 08:15AM  Rosetta Genomics Initiates Post-Marketing Registry Study of Its Cancer Origin Test Marketwired
02-Sep-14 01:40PM  Rosetta Genomics to Participate in September Investor Conferences Marketwired
08:15AM  Rosetta Genomics and Moffitt Cancer Center Enter Into Strategic Alliance to Develop microRNA-Based Cancer Diagnostics Marketwired
18-Aug-14 08:45AM  Rosetta Genomics Expands Management Team With Appointment of Douglas Sites as Executive Vice President of Sales and Marketing Marketwired +5.15%
31-Jul-14 08:15AM  Rosetta Genomics Announces Agreement With Global Pharmaceutical Company to Advance Efforts in Alzheimer's Disease Diagnostics Marketwired
29-Jul-14 08:45AM  Rosetta Genomics Announces Next-Generation Sequencing Research Collaboration With Weizmann Institute of Science's Nancy and Stephen Grand Israel National Center for Personalized Medicine Marketwired
22-Jul-14 09:30AM  Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test Marketwired
10-Jul-14 09:00AM  Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer Marketwired +6.17%
27-Jun-14 09:40AM  ROSG: Collaboration Accelerates Product Development and Represents New Avenue for Revenue Growth Zacks Small Cap Research
26-Jun-14 09:43AM  Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of Prostate Cancer Marketwired
09-Jun-14 08:10AM  UPDATE: Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of microRNA-Based Cancer Diagnostic Marketwired
07:15AM  Rosetta, Moffitt enter into agreement for thyroid neoplasia assay at theflyonthewall.com
07:02AM  Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of microRNA-Based Cancer Diagnostic Marketwired
04-Jun-14 10:33AM  UPDATE: Barrington Research Initiates Coverage On Rosetta Genomics Ltd. On Good Market Position Benzinga
05-Apr-14 01:04PM  ROSETTA GENOMICS LTD. Financials EDGAR Online Financials
04-Apr-14 08:15AM  Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay Marketwired
02-Apr-14 09:08AM  Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases Marketwired
08:00AM  ROSG: Three Platforms Will Drive Revenue Growth in 2014 and Beyond Zacks Small Cap Research
01-Apr-14 10:00AM  Full Year 2013 Rosetta Genomics Ltd Earnings Call scheduled for 10:00 am ET today CCBN
31-Mar-14 06:05PM  Rosetta Genomics Reports 2013 Financial Results Marketwired
03:17PM  Notable companies reporting after market close at theflyonthewall.com
07:07AM  Full Year 2013 Rosetta Genomics Ltd Earnings Release - After Market Close CCBN
25-Mar-14 02:50PM  Rosetta Genomics to Host Business Update Conference Call on April 1, 2014 Marketwired -5.41%
24-Mar-14 09:15AM  Rosetta Genomics Enters Collaboration With Clalit Health Services' Rabin Medical Center for microRNA-Based Assay for Chronic Allograft Dysfunction Following Kidney Transplantation Marketwired
21-Mar-14 12:15PM  Rosetta Genomics' Cancer Origin Test Highlighted at Landmark CUP Foundation Seminar 2014 Marketwired -9.47%
12-Mar-14 11:00AM  Rosetta Genomics: Pipeline Provides Sustainable Growth Zacks Small Cap Research
08:15AM  Rosetta Genomics Provides Product Pipeline Update Marketwired
07-Mar-14 08:21AM  Rosetta Genomics: The Leader In MicroRNA-Based Molecular Diagnostics at Seeking Alpha
06-Mar-14 08:10AM  Rosetta Genomics (ROSG) - Initiating with an Outperform Zacks Small Cap Research +6.59%
03-Mar-14 09:15AM  Rosetta Genomics Announces Publication of Data Correlating miR-150 to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure Marketwired
26-Feb-14 08:45AM  Rosetta Genomics to Receive Important U.S. Patent for Oncology Therapeutic Marketwired
18-Feb-14 08:45AM  Rosetta Genomics Executes Agreement With MultiPlan Marketwired
08:25AM  Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care Marketwired
21-Jan-14 08:30AM  Rosetta Cancer Origin Test Now Covered by Highmark Health Services, the Fourth Largest U.S. Blue Cross and Blue Shield-Affiliated Company Marketwired +8.19%
16-Jan-14 07:59AM  Rosetta Genomics platform predicts bladder cancer progression in published study at theflyonthewall.com
07:54AM  Rosetta Genomics' Platform Predicts Bladder Cancer Progression in Study Published in Urologic Oncology: Seminars and Original Investigations Marketwired
13-Jan-14 08:00AM  Rosetta Genomics Announces Master Service Provider Agreement With a Major, Global Biopharmaceutical Company Marketwired +18.18%
11-Dec-13 10:29AM  Recapping Recent Events In Rosetta Genomics - 2014 Could Be A Breakout Year at Seeking Alpha +5.32%
10-Dec-13 09:00AM  Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology Marketwired
09-Dec-13 08:30AM  Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test(TM) Marketwired
02-Dec-13 09:02AM  InPlay: Rosetta Genomics issues letter to shareholders; says 'November was by far the strongest month for our Cancer Origin Test... we estimate our gross billings will pass the $1 million dollar mark by year-end' Briefing.com
09:00AM  Rosetta Genomics Issues Letter to Shareholders Marketwired
27-Nov-13 09:10AM  Rosetta Genomics to Participate in the LD Micro Conference Marketwired
20-Nov-13 08:30AM  Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania Marketwired
07-Nov-13 09:06AM  Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer Marketwired
06-Nov-13 08:30AM  Rosetta Genomics Reports First Payment From the UK's National Health Service for the Rosetta Cancer Origin Test(TM) Marketwired
31-Oct-13 08:53AM  Rosetta Genomics announces sponsored research agreement with Ramot at TAU at theflyonthewall.com
08:30AM  Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv University Marketwired
30-Oct-13 10:03AM  Rosetta Genomics downgraded by Aegis Capital Briefing.com -12.90%
22-Oct-13 09:44AM  Rosetta Genomics receives USPTO patent for lung cancer test at theflyonthewall.com
Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. It offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. The company also focuses on developing tissue-based microRNA biomarkers for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction; microRNA-based diagnostic test for the early diagnosis of Alzheimer's disease; and blood- or urine-based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. The company has a collaboration agreement with Clalit Health Services for the development of a non-invasive microRNA-based assay for the diagnosis of chronic allograft dysfunction or chronic rejection, following kidney transplantation; a strategic alliance with Marina Biotech, Inc. to develop microRNA-based diagnostics and therapeutics for rare diseases; and a collaboration agreement with Biocept, Inc. to evaluate microRNAs from circulating tumor cells. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.